Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M104365200 on January 17, 2002

J. Biol. Chem., Vol. 277, Issue 14, 12175-12181, April 5, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/14/12175    most recent
M104365200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mushtaq, A.
Right arrow Articles by Sim, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mushtaq, A.
Right arrow Articles by Sim, E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The COOH Terminus of Arylamine N-Acetyltransferase from Salmonella typhimurium Controls Enzymic Activity*

Adeel MushtaqDagger, Mark Payton, and Edith Sim

From the Department of Pharmacology, University of Oxford, Mansfield Road, Oxford OX1 3QT, United Kingdom

Received for publication, May 14, 2001, and in revised form, December 18, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Arylamine N-acetyltransferases (NATs) are a homologous family of enzymes, which acetylate arylamines, arylhydroxylamines, and arylhydrazines by acetyl transfer from acetyl-coenzyme A (Ac-CoA) and are found in many organisms. NAT was first identified as the enzyme responsible for the inactivation of the anti-tubercular drug isoniazid in humans. The three-dimensional structure of NAT from Salmonella typhimurium has been resolved and shown to have three distinct domains and an active site catalytic triad composed of "Cys69-His107-Asp122," which is typical of hydrolytic enzymes such as the cysteine proteases. The crystal unit cell consists of a dimer of tetramers, with the C terminus of individual monomers juxtaposed. To investigate the function of the first two domains of full-length NAT from S. typhimurium and to investigate the role of the C terminus of NAT, truncation mutants were made with either the C-terminal undecapeptide or the entire third domain (85 amino acids) missing. Unlike the full-length NAT protein (281 amino acids), the truncation mutants of NAT from S. typhimurium are toxic when overexpressed intracellularly in Escherichia coli. Full-length NAT hydrolyses Ac-CoA but only in the presence of an arylamine substrate. Both truncation mutants, however, hydrolyze Ac-CoA even in the absence of arylamine substrate, illustrating that the C-terminal undecapeptide controls hydrolysis of Ac-CoA by NAT from S. typhimurium.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Arylamine N-acetyltransferases (NATs,1 EC 2.3.1.5) vary in size from 30 to 34 kDa and form a distinct protein family (1). These enzymes are found in a range of species from prokaryotes to humans and catalyze the acetylation of many arylamine and arylhydrazine compounds by catalyzing the transfer of an acetyl group from acetyl-coenzyme A (Ac-CoA) to the terminal amino group of the substrate. This activity plays an important role in the metabolism of drugs and xenobiotics (2-4). It has also been proposed that a possible endogenous role for NATs in humans is in the acetylation of a folate catabolite, p-aminobenzoyl glutamate (5, 6), but as yet no endogenous substrate is known for NATs in prokaryotes, although NAT activity has been identified in prokaryotes, including several Mycobacteria (7-11). While the members of the NAT family may have a common function it is also possible that individual NATs carry out different roles in the various organisms in which they have been found. The existence of the NAT homologue, rifamycin-amide synthase (12, 13), which is involved in the cyclization of an arylamine precursor to form the antibiotic rifamycin in Amycolatopsis mediterrani also indicates that NATs may have differing roles in different organisms.

NAT from Salmonella typhimurium was first identified from strains of the bacterium used in the Ames test for carcinogens (14) and it was also subsequently shown to be involved in the activation of hydroxyarylamine carcinogens by O-acetylation (2, 15, 16). Previously, kinetic studies on NAT from pigeon livers showed the necessity of a sulfhydryl group for activity (17-19). It was also these studies that led to the first suggestion of a "ping-pong" mechanism involving a thio-acetyl intermediate.

Recently, the structure of NAT from S. typhimurium (ST-281), which consists of 281 amino acid residues, was determined (20). The structure revealed a unique fold, which has three distinct domains (Fig. 1). The first two domains (Fig. 1a) showed similarity to the structure of proteins in the "papain" family of cysteine proteases such as staphopain (21). The structure of NAT illustrated the presence of a "Cys69-His107-Asp122" catalytic triad, also found in the cysteine proteases (22). The three amino acid residues of the catalytic triad are found in the first two domains of NAT from S. typhimurium (Fig. 1a) and are conserved in all members of the NAT family (20). This structural similarity of NAT to the cysteine proteases suggested that NATs and the cysteine proteases might have evolved from a common ancestor. The structure of the unit cell of crystalline NAT from S. typhimurium is a pair of tetramers with each tetramer consisting of a pair of dimers. The C termini (~residues 270 and beyond) of the monomers in the individual dimers (Fig. 1a) are not visible in the solved structure of NAT but must be in very close proximity from the juxtaposition of the monomers in the unit cell (Fig. 1b) (23).

We have investigated the function of the first two domains of full-length NAT from S. typhimurium, which corresponds to 196 amino acid residues, and the role of the C terminus of NAT, by making truncation mutants with either the C-terminal undecapeptide (AAFDTHPEAGK) or the entire third domain missing (Fig. 1). Here we report that these truncation mutants of NAT from S. typhimurium are toxic when overexpressed intracellularly in Escherichia coli. We also demonstrate that only the truncation mutants hydrolyze Ac-CoA in the absence of substrate and illustrate that the C-terminal undecapeptide is essential in modulating hydrolysis of Ac-CoA by NAT from S. typhimurium.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cloning-- Fragments of the gene encoding full-length S. typhimurium NAT were cloned following amplification of the regions from the open reading frame of NAT in genomic DNA from S. typhimurium (Strain L2, from Jay Hinton, IMM, Oxford). The forward primer 5'-AGTCACTCATATGACCTCTTTTTTACAT-3' and reverse primers 5'-ATTTTGTAAGCGGCCGCTCACATTACCGCGGCCAGCTC-3' and 5'-ATTTTGTAAGCGGCCGCTCATTGCGGCCAGTGAGCCGA-3' were used to amplify 589- and 811-bp fragments, respectively, which encode for the first 196 amino acids (st-196) and 270 amino acids (st-270) of full-length S. typhimurium NAT (st-281). The 589- and 811-bp fragments were ligated into the vector pGEMT (Promega) and transformed into E. coli strain JM109 (Promega). The inserts were then subcloned into the expression vector pET 28b(+) (Novagen Inc., Madison, WI), immediately after the region encoding the hexa-histidine tag, using the NotI and NdeI restriction sites (shown in bold) at the 5' and 3' ends, respectively. The plasmids, now with open reading frames corresponding to nst-196 and nst-270, were then transfected into E. coli strain BL21(DE3)pLysS (Promega). The nst-196,nst-270 fragments and the open reading frame of S. typhimurium NAT, inclusive of a N-terminal hexa-histidine tag (nst-281) were further subcloned from pET28b(+), into the vector pBAD/gIII (24) (Invitrogen Inc., Groningen, Holland) using the NcoI and XhoI sites, followed by transformation of the pBAD/gIII vectors into E. coli strain TOP 10 (Invitrogen), for propagation and expression. The sequences of the open reading frames of the final constructs were confirmed.

Expression of nst-281, nst-270, and nst-196 Using pET28b(+)-- Cultures (1 liter of LB containing chloramphenicol (34 µg/ml) and kanamycin (30 µg/ml)) of BL21(DE3)pLysS cells containing one of the pET28b(+) constructs (encoding NST-281, NST-270, or NST-196) were grown (A600 of 0.6) at 27 °C (with 1 M sorbitol (10 h)) or at 37 °C (2.5 h) and then induced with either 0.1 or 1 mM isopropyl-beta -D-thiogalactopyranoside (IPTG) with 2.5 mM betaine added for cultures at 27 °C. Cultures (A600 of 1 -1.2) were harvested (7,000 × g, 4 °C, 10 min) and the pellets were each resuspended in 40 ml of lysis buffer (10 mM Tris-HCl, 1 mM EDTA at pH 8.0 containing 10 mM CaCl2, 0.5 mg/ml lysozyme, 0.1 mg/ml DNase I, and 1 mM Pefabloc SC (Pentapharm Ltd., Herts, UK)) and kept on ice for 30 min followed by 3 freeze-thaw cycles between liquid nitrogen and 42 °C. After incubation (37 °C, 30 min) and centrifugation (15,000 × g, 4 °C, 15 min), the soluble fraction was collected and the pellet was resuspended in the same volume of lysis buffer containing Tween 20 (1% (v/v)).

Testing for the Stability of the pET28b(+) Plasmid in E. coli-- Cultures of BL21(DE3)pLysS cells containing each of the pET28b(+) constructs (encoding nst-281, nst-270, or nst-196) were grown (A600 of 1) in LB (chloramphenicol (34 µg/ml) and kanamycin (30 µg/ml)) followed by dilution between 105 and 2 × 106-fold before plating 1 ml on LB agar plates, containing 34 µg/ml chloramphenicol with or without kanamycin (30 µg/ml) and/or IPTG (1 or 0.1 mM) (25, 26). After 12 h at 37 °C the number of growing colonies was counted.

Expression of nst-281, nst-270, and nst-196 Using pBAD/gIII-- Cultures (1 liter of LB containing 50 µg/ml ampicillin) of the E. coli strain TOP 10 containing one of the pBAD/gIII constructs (nst-281, nst-270 or nst-196) were grown at 37 °C, with shaking, to an A600 of ~0.5 (2-3 h) and then induced (4 h) with either 0.002% (w/v) L-arabinose (NST-281) or 0.2% (w/v) L-arabinose (NST-270 and NST-196). Soluble fractions were collected as described above. Where indicated, cells were osmotically shocked with a 20% sucrose solution (24), and the periplasmic fraction was removed by 3 cycles of centrifugation (15,000 × g, 15 min) and washing (10 mM Tris-HCl, 2.5 mM EDTA, pH 8.0). The remaining spheroplasts were then lysed, with lysis buffer as for the whole cells, and the soluble fraction, corresponding to the cytoplasm, was collected following centrifugation (15,000 × g, 4 °C, 15 min).

Purification of NST-281, NST-270, or NST-196-- Recombinant proteins and a mock expression control (empty pBAD/gIII vector) were purified using Ni-NTA affinity chromatography (20, 27).

Protein concentrations of soluble fractions were determined by measuring the absorbance at 280 nm or by using the Bradford assay (28). NAT protein in insoluble fractions was quantitated following Western blotting by comparison with known amounts of soluble pure NST-281.

Protein samples were denatured, reduced, and alkylated for 12% SDS-PAGE (29). Gels were stained with Coomassie Blue (30) or probed for NAT by Western blotting using a rabbit polyclonal antiserum against pure ST-281 (11).

Enzymic Activities-- Enzymic activities were determined (17, 18, 27) using soluble fractions of freshly prepared bacterial cell lysates, unless otherwise stated. All Michaelis constants, Km, and maximum rates, Vmax, were calculated using nonlinear optimization (max iterations = 200) (31-33) from activities measured in duplicate at a minimum of five substrate concentrations.

Three different enzymic activities were determined. (A) Arylamine N-acetyl transfer activity was measured using acetyl-CoA and 4-aminoveratrole (4AV), p-anisidine (ANS), or isoniazid (INH). Reactions, containing up to 2 mM acetyl donor or acceptor, were carried out in a total volume of 200 µl (20 mM Tris-HCl, 1 mM EDTA, and 1 mM dithiothreitol, pH 7.5) at 37 °C and stopped by addition of an equal volume of 20% (w/v) trichloroacetic acid (4 °C). The loss of arylamine substrate was determined spectrophotometrically (27, 34) or by high performance liquid chromatography (35). (B) The enzymatic hydrolysis of Ac-CoA to CoA was determined using dithiobis(2-nitrobenzoic acid). Reactions were carried out as in A except without dithiothreitol. The quantity of CoA generated was determined by measuring the absorbance, at 410 nm, of the CoA-dithiobis(2-nitrobenzoic acid) conjugate as previously described (17). (C) Hydrolysis of p-nitrophenyl acetate (PNPA) was determined by the rate of formation of p-nitrophenol at 410 nm. The enzyme solution (final volume 1 ml) contained between 50 pg and 1 µg of pure protein in 20 mM Tris-HCl and 1 mM EDTA at pH 7.5 with the addition of 2 mM INH as required. PNPA (final concentration up to 4 mM) was then added to the enzyme solution (pre-heated to 37 °C) to start the reaction. The final concentration of acetonitrile (used to dissolve PNPA) stock was less than 0.1% (v/v) and had no effect on enzymic activity as determined using methods A and B.

Simulated "in Silico" Docking of Substrates-- All non-polar hydrogen and terminal oxygen atoms were attached and Gasteiger charges were assigned to the three-dimensional protein structure of NAT from S. typhimurium (PDB accession number 1E2T) using the program SYBYL 6.5 (36). Three-dimensional structures of substrates, in MOL2 format, were created using SYBYL 6.5 and rotatable bonds and fixed rings were assigned using the program AUTOTORS (37).

The substrate structures were then annealed to the protein structure in silico using the AUTODOCK suite of programs (38). The lowest energy docking solutions were then viewed and analyzed using SPDBV (39).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression of nst-281, nst-270, and nst-196 in the Cytosol of E. coli Using pET 28b(+)-- NST-270 and NST-196, which correspond to NAT from S. typhimurium containing an N-terminal hexa-histidine tag with either the C-terminal 11 amino acids or entire third domain missing, respectively (Fig. 1), were produced as recombinant proteins in E. coli. NST-270 and NST-196 were found in inclusion bodies although the level of recombinant protein was very low (<100 µg/l of culture). In contrast, NST-281, which corresponds to the full-length NAT from S. typhimurium containing an N-terminal hexa-histidine tag, is soluble and recovered in high yield (~2 mg/liter of culture). When higher concentrations of IPTG (up to 1 mM) were used the level of expression of NST-270 and NST-196 was greater, but still the amount of soluble protein produced, was too low to be detected by Western blotting. No improvement in solubility of NST-270 and NST-196 was obtained when cultures were grown slowly (27 °C), a procedure which had previously proved successful in generating soluble recombinant proteins (10).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 1.   The three-dimensional crystal structure of NAT from S. typhimurium. a, cartoon topology of the structure of a monomer of NAT from S. typhimurium (ST-281), in three distinct domains. Standard nomenclature is used for the structural annotation and the amino acid sequence is given below the structure in single letter format. The protein sequence of the first two domains of ST-281 is colored black with the sequence of the third domain being colored green followed by the final C-terminal undecapeptide, which is colored magenta. Residues in the sequence with triangles above them indicate amino acid residues of the "catalytic triad." The PDB accession number of ST-281 is 1E2T and the structural topology was created using "PDBsum" (50). b, a three-dimensional representation of the structure of a dimer of NAT from S. typhimurium (ST-281). The unit cell consists of a dimer of tetramers, with each tetramer being composed of a pair of dimers. Each secondary structure element is colored successively from the N terminus to the C terminus for each individual monomer (blue through to green for monomer B and then green through to red for monomer A).

Toxicity of NST-270 and NST-196 Proteins in the Cytosol of E. coli-- To determine whether the low level of expression of the truncated proteins was due to toxicity, plasmid stability tests were carried out (25). Colonies of BL21(DE3)pLysS, containing the pET28b(+) vector with inserts encoding NST-270 or NST-196 were grown on LB agar plates with or without kanamycin/IPTG combinations to determine the number of colonies retaining the pET28b(+) plasmid with the different inserts (26, 40, 41). The ratio of the number of colonies growing on plates containing IPTG to plates containing both IPTG and kanamycin was used to determine the percentage of colonies that had lost their plasmid. Of the colonies that contained plasmids with the inserts encoding for NST-270 and NST-196, 36 and 43%, respectively, lost their plasmid in the presence of either 1 or 0.1 mM IPTG. For comparison, the same experiment with NST-281 showed that in the presence of 1 or 0.1 mM IPTG, only 10 or 4% of colonies, respectively, had lost the plasmid with the nst-281 insert.

Expression of nst-281, nst-270, and nst-196 Using pBAD/gIII-- Expression in the pBAD/gIII system leads to transport of recombinant protein, prior to folding, from the cytoplasm to the periplasm by means of the gIII signal peptide, which is cleaved once the protein reaches the periplasm (24, 42). However, for NST-270, ~50% of recombinant protein was found in the cytoplasm with the gIII signal still attached, as determined on the basis of molecular weight using Western blotting (Fig. 2 


View larger version (22K):
[in this window]
[in a new window]
 
Recombinant NST-281, NST-270, and NST-196 in the periplasm of E. coli (TOP 10) expressed from the pBAD/gIII vector. a, SDS-12% PAGE analysis followed by Coomassie Blue staining of whole cell lysates of the (15 µg of total protein/lane) NST-281, NST-270, and NST-196 recombinant proteins, as indicated, expressed using the pBAD/gIII vector. Whole cell lysate from cells transfected with empty vector alone are also shown for comparison. The same number of cells prior to lysis is loaded in each lane. Molecular weight marker was loaded in the far left lane. b, SDS-12% PAGE followed by Western blot analysis of whole cell lysates. Individual lanes were loaded with the whole cell lysate, pellet, or supernatant (containing both cytosol and periplasm) fractions after expression of nst-280, nst-270, or nst-196 as indicated. Approximately 1 µg of total protein was loaded into each lane. The lower gel shows the pellet, supernatant (cytoplasm and periplasm), and separated cytosolic fraction for NST-270 after removal of the periplasm by osmotic shock, as described under "Experimental Procedures." c and d, effect on production of soluble recombinant proteins by varying the concentration of arabinose used for induction. SDS-12% PAGE followed by Western blot analysis of the soluble fractions of E. coli cell lysates after expression of nst-281, nst-270, and nst-196 as indicated. Expression of nst-281 and nst-270 was induced with different amounts of arabinose (mg/liter) as shown below individual lanes. Approximately 2 µg of total protein was loaded into each lane.
b). Minor contamination from protein in the pellet could not be avoided when separating cytoplasmic and periplasmic fractions.

Expression of nst-270 and nst-196, using this system, resulted in much higher levels of expression than using the pET system (Fig. 2a). The quantity of soluble truncated proteins recovered was, however, much less than for NST-281 (1 mg/liter culture) when expressed using the pBAD/gIII system under similar conditions (Fig. 2b). All three recombinant proteins could nevertheless be affinity purified from the soluble fraction of cell lysates. Typically the N-terminal hexa-histidine-tagged proteins were eluted with 50 mM imidazole yielding pure protein. Unlike NST-281, the NST-196 and NST-270 proteins lost a large proportion of enzymic activity during purification and were observed to precipitate rapidly in high salt (300 mM), which is required for purification. The enzymic activity of NST-270 and NST-196 in lysates was unstable and could not be detected after 3 days at 4 °C. Therefore lysates were used for activity assays within hours of preparation. These observations were in contrast to those for NST-281, which was stable, both when stored as lysate and during purification following expression using the pBAD/gIII system. During the purification of NST-270, the higher molecular weight protein corresponding to NST-270 with the uncleaved gIII signal peptide (~32,000) (Fig. 2b) eluted at a different concentration of imidazole (250 mM) to NST-270. This protein (NST-270 with the gIII signal sequence attached) was enzymatically inactive.

Enzymic Analysis of Recombinant NAT Proteins-- All proteins were assessed for N-acetyltransferase, Ac-CoA hydrolysis, and PNPA hydrolysis activities as shown in Tables I and II. PNPA resembles an acetylated arylamine (Fig. 3).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Kinetic parameters for acetylation of arylamines
Kinetic parameters for the transfer of the acetyl group of Ac-CoA to arylamine substrates are given. No acetyl transfer activity was detected for the NST-196 protein using the substrates ANS, 4-AV, or INH. Maximum velocity values are given in picomoles per minute per mg of total soluble protein.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Effect of INH on the kinetic parameters for hydrolysis of Ac-CoA and PNPA
Kinetic parameters for the enzymic hydrolysis of Ac-CoA and PNPA were determined in the presence or absence of isoniazid (INH). Maximum velocity values are given in picomoles per minute per mg of total soluble protein except with PNPA where picomoles per minute per mg of pure protein is used.


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 3.   Simulated docking of substrates into the structure NAT from S. typhimurium (ST-281). a, the structures of the arylamine substrates, ANS and 4AV, are shown along with the structure of the arylhydrazine substrate INH and acetyl donor PNPA. The acetylated product acetyl-anisidine (Ac-ANS) is also shown. The docking energies at the alpha  and beta  sites, as shown below the respective structures, are given in kJ/mol. b, representation of the docking solutions of ANS into binding site beta  and PNPA into binding site alpha  of the structure ST-281 as determined by simulated docking using the AUTODOCK suite of programs (38). The protein structure of ST-281 is shown in ribbon form with the residues of the catalytic triad also indicated.

Arylamine N-acetyltransferase activity was observed only for the NST-281 and NST-270 proteins. However, the Km values for both proteins, with Ac-CoA, were too low (less than 20 µM) to be determined accurately, using the high performance liquid chromatography method employed (35). Enzymatic cleavage of Ac-CoA was observed with all three recombinant proteins in the presence of 2 mM INH. When INH was not present, only NST-270 and NST-196 hydrolyzed Ac-CoA as shown in Table II. The hydrolysis of the acetyl donor PNPA, also only occurs with NST-281 in the presence of INH. However, there are distinct differences in the pattern of hydrolysis of both Ac-CoA and PNPA (Table II), by the full-length and truncated NATs. The Michaelis constant obtained for NST-281 expressed using the pBAD/gIII system was similar to that obtained for NST-281 using the pET system in previous studies (27), indicating that expression in the pBAD/gIII system has not adversely affected the kinetic values.

Simulated Docking of Substrates-- The structures of 4AV, ANS, INH, PNPA, and the acetylated forms of INH (Ac-INH) and ANS (Ac-ANS) (Fig. 3a) were docked into the structure of NAT from S. typhimurium and the lowest energy binding sites were determined in each case. The sites described are an order of magnitude lower in energy than the next best solutions.

The docking, of PNPA, revealed a preferential binding pocket (site alpha ) for the benzene ring. The aromatic ring of PNPA appeared to interact with Phe125, which is conserved in all prokaryotic NATs, by a "pi -pi ring stacking" interaction with a docking energy of -21.1 kJ/mol (-5.05 kcal/mol). The binding site alpha  was almost identical in position to that for 4-bromoacetanilide (an irreversible inhibitor covalently bound to the Cys69 residue) as determined from the crystal structure of NAT from S. typhimurium with the inhibitor bound (20) (Fig. 3b).

The second series of docking studies were with substrates 4AV, ANS, and INH. These compounds bind similarly to PNPA in site alpha . Additionally, these substrates, but not PNPA, were also bound at a second site (beta ) (Fig. 3b). The interaction of the substrates at the second site appeared to be with residues Ile36, Pro37, and Phe38. These residues have previously been suggested to contribute to Ac-CoA binding (11). The docking energy for 4AV, ANS, and INH was lower at site beta  than at site alpha  (Fig. 3), indicating that 4AV, ANS, and INH bind at site beta  in preference to site alpha . It would be highly unlikely for acetyl transfer to occur at site beta  because of the 9.1-Å distance between the terminal nitrogen of a substrate bound at site beta  and the sulfydryl of Cys69 (Fig. 3b). However, any substrate subsequently bound in the higher energy site alpha , would have its terminal nitrogen (or oxygen for PNPA) close enough to the active site Cys69 (3.0 Å) to allow transfer of an acetyl group to and from the sulfhydryl group. No significant binding sites were identified for the acetylated substrates, Ac-INH and Ac-4AV.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

When the truncated versions of NST-281 (NST-270 and NST-196) are generated as recombinant proteins using the pET28b(+) system there is very little protein produced compared with the production of NST-281. The pET28b(+) plasmids encoding for nst-270 and nst-196 are approximately four times more unstable, in E. coli, than the plasmid encoding for nst-281, suggesting that the NST-270 and NST-196 proteins are much more toxic than NST-281. This serves to explain why so little recombinant NST-270 and NST-196 is produced (26). The minimal toxicity of the NST-281 protein can be attributed to the large quantity of soluble recombinant protein being produced disrupting usual cell function (41). The toxicity of the truncation mutants is likely to be due to an enzymic activity, rather than to accumulation of protein, as very little NST-270 or NST-196 protein was produced. An analogous situation has been observed with zymogens (such as trypsinogen), which are only toxic when expressed in bacteria, if the inactivating peptide at the N terminus is missing (43).

When the nst-196, nst-270, and nst-281 proteins were expressed under conditions in which the recombinant proteins were excreted into the periplasmic space (24, 42, 44), much higher levels of expression for soluble NST-270 and NST-196 proteins (Fig. 2) were observed relative to expression using the pET system. The quantity of soluble NST-270 and NST-196 proteins produced in the periplasmic space was low relative to the production of soluble NST-281 (Fig. 2, c and d). It thus appears that the folded structure of NST-281 is more stable than the structures of NST-270 and NST-196 and suggests that the C-terminal region is essential for the stability of the complete NST-281 fold. However, the enzymic activity of the NST-270 and NST-196 proteins indicated clearly that low levels of correctly folded proteins were present. Soluble, but inactive, NST-270 (with the gIII signal still attached) was found in the cytosol and is unlikely to be folded correctly since one of the features of the gIII transport system is that folding of recombinant proteins is only completed after transport to the periplasm (24, 42).

The acetyltransferase and hydrolytic activities of the truncated versions of S. typhimurium NAT were different from those of the full-length protein. The NST-281 and NST-270 proteins catalyzed the acetyl transfer from Ac-CoA to 4AV, ANS, or INH whereas NST-196, which completely lacks the third domain, showed no such activity. The lack of acetyltransferase activity for NST-196 confirms that the third domain of NST-281 is essential for the acetylation step (19). This has been shown previously for human NAT1 (45) and suggests a common domain structure for both NST-281 and human NAT1. The similarity of the Km values of NST-270, for the acetylation of the arylamines 4AV and ANS (200 µM), indicates that the relative affinity for these two arylamine substrates has been abolished in the shorter form of the protein. The Km values, with NST-270, for both substrates (4AV and ANS) were lower than those for NST-281 suggesting that the apparent affinity of NST-270 for the arylamine substrates is greater than the apparent affinity of NST-281 for the same substrates. In contrast, the Km value of NST-270 for Ac-CoA is over 8-fold greater than that of NST-281 (Tables I and II). The apparent affinity for Ac-CoA is much reduced on removal of the C terminus of NST-281. This suggests that the C-terminal undecapeptide plays an important role in substrate and Ac-CoA binding, possibly by occluding access to the active site of the opposing NST-281 monomer if a dimer exists in solution (Fig. 1). The dependence of the Km values, for the hydrolysis of Ac-CoA by NST-270 and NST-196, on the presence of INH (Table I) indicates that binding of Ac-CoA also requires the presence of INH.

Only NST-270 and NST-196 hydrolyze Ac-CoA when there is no INH present, which serves to explain the higher toxicity of these recombinant proteins in the cytosol of E. coli. Intracellular concentrations of Ac-CoA have been measured to be of the order of 1 mM in E. coli (46, 47) and at this concentration of Ac-CoA it would be expected that the truncated proteins, NST-270 and NST-196, would compete effectively with other endogenous Ac-CoA-dependent enzymes, which are present in the cytosol of E. coli. The recombinant NST-281 protein, in contrast, would not compete in the absence of arylamine substrate. The control of hydrolysis of Ac-CoA is therefore likely to be an important function of the C terminus of NST-281, although it is still unknown how the hydrolysis of Ac-CoA, in the absence of arylamine substrate, is prevented in NST-281.

The simulated docking of 4AV, ANS, and INH to NAT from S. typhimurium revealed two binding sites (alpha  and beta ) for the aromatic substrates (Fig. 3b). In contrast, docking of PNPA showed it was bound only at one site corresponding to the substrate-binding site alpha . The lack of good binding of the acetylated substrates (AC-INH, Ac-4AV) also suggests that, once acetylated, the substrates do not remain bound to the protein. Site beta  is in close proximity (~5 Å) to the putative "P-loop" which has been considered as a possible binding region for the phosphate groups of Ac-CoA in NAT from S. typhimurium (20) suggesting that site beta , rather than site alpha , may be involved in Ac-CoA binding.

The mode of interaction between NST-281 and Ac-CoA is unclear, although a very strong "ring stacking" interaction between an aromatic moiety and the adenosine ring of Ac-CoA has previously been demonstrated in solution (48, 49). It is thus possible that the arylamine substrate initially binds in site beta  to form a new Ac-CoA-binding site in which the aromatic ring of the substrate can "ring stack" with the adenosine ring in Ac-CoA. This would serve to explain the lack of hydrolysis in the absence of INH for NST-281 and would also explain the lower Km values for the hydrolysis of Ac-CoA by NST-270 and NST-196 in the presence of INH, although it is clear that the C-terminal undecapeptide must also play a role in regulation of the binding of Ac-CoA.

It is therefore proposed that the NAT protein must initially bind arylamine substrate (at site beta ) to initiate a conformational change, which allows the subsequent binding of Ac-CoA and the acetylation of the active site cysteine. Subsequent acetyl transfer can then occur from the acetylated-protein intermediate to the substrate (now bound at site alpha ).

In conclusion, the C terminus of NAT from S. typhimurium regulates the binding of Ac-CoA in the absence of substrate such that there is control over hydrolysis of Ac-CoA. It is also possible that the first two domains of NAT from S. typhimurium and the corresponding domains of the cysteine proteases have evolved from a common ancestor with the third domain of NAT from S. typhimurium acting to regulate the hydrolytic function of the NAT protein.

    ACKNOWLEDGEMENTS

We thank Drs. Katalin Pinter, Martin Noble, John Sinclair, Dawn O'Reilly, and Grant Churchill for helpful discussion and advice. We also thank James Sandy for technical assistance.

    FOOTNOTES

* This work was supported by the Wellcome Trust and a Medical Research Council (United Kingdom) studentship (to A. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Pharmacology, University of Oxford, Oxford, OX1 3QT, United Kingdom. Tel.: 44-1865-271595; Fax: 44-1865-271853; E-mail: adeel.mushtaq@pharm.ox.ac.uk.

Published, JBC Papers in Press, January 17, 2002, DOI 10.1074/jbc.M104365200

    ABBREVIATIONS

The abbreviations used are: NAT, arylamine N-acetyltransferase; ANS, p-anisidine(4-methoxyaniline); 4AV, 4-aminoveratrole (3,4-dimethoxy aniline); INH, isoniazid; PNPA, 4-nitrophenyl acetate; ST-281, full-length (281 residues) NAT protein from S. typhimurium; NST-281, recombinant ST-281 with an N-terminal hexa-histidine tag; NST-270, recombinant protein corresponds to N-terminal 270 amino acid residues of ST-281 with an N-terminal hexa-histidine tag; NST-196, recombinant protein corresponds to N-terminal 196 amino acid residues of ST-281 with an N-terminal hexa-histidine tag; IPTG, isopropyl-beta -D-thiogalactopyranoside; Ac-CoA, acetyl-coenzyme A.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Upton, A., Johnson, N., Sandy, J., and Sim, E. (2001) Trends Pharmacol. Sci. 22, 140-146
2. Hein, D. W., Rustan, T. D., Doll, M. A., Bucher, K. D., Ferguson, R. J., Feng, Y., Furman, E. J., and Gray, K. (1992) Toxicol. Lett. 123-130
3. Hein, D. W., Rustan, T. D., Ferguson, R. J., Doll, M. A., and Gray, K. (1994) Arch. Toxicol. 68, 129-133
4. King, C. M., Land, S. J., Jones, R. F., Debiec-Rychter, M., Lee, M. S., and Wang, C. Y. (1997) Mutat. Res. 12, 123-128
5. Minchin, R. F. (1995) Biochem. J. 307, 1-3
6. Upton, A., Smelt, V., Mushtaq, A., Aplin, R., Johnson, N., Mardon, H., and Sim, E. (2000) Biochim. Biophys. Acta 1524, 143-148
7. Chung, J., Wang, H., Tsou, M., Hsieh, S., Lo, H., Yen, Y., Chang, S., Wu, L., Lee, J., and Hung, C. (1997) Toxicol. Lett. 91, 63-71
8. Chung, F. C., and Chung, G. C. (1998) Curr. Microbiol. 3, 125-130
9. Delomenie, C., Fouix, S., Longuemaux, S., Brahimi, N., Bizet, C., Picard, B., Denamur, E., and Dupret, J.-M. (2001) J. Bacteriol. 183, 3417-3427
10. Payton, M., Auty, R., Delgoda, R., Everett, M., and Sim, E. (1999) J. Bacteriol. 181, 1343-1347
11. Payton, M., Mushtaq, A., Yu, T. W., Wu, L. J., Sinclair, J., and Sim, E. (2001) Microbiology 147, 1137-1147
12. Floss, H., and Yu, T.-W. (1999) Curr. Opin. Chem. Biol. 3, 592-597
13. Yu, T.-W., Shen, Y., Doi-Katayama, Y., Tang, L., Park, C., Moore, B., Hutchinson, C., and Floss, H. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 9051-9056
14. Watanabe, M., Nohmi, T., and Ishidate, M., Jr. (1987) Biochem. Biophys. Res. Commun. 147, 974-979
15. Josephy, P. D., Evans, D. H., Parikh, A., and Guengerich, F. P. (1998) Chem. Res. Toxicol. 11, 70-74
16. Dang, L. N., and McQueen, C. A. (1999) Toxicol. Appl. Pharmacol. 159, 77-82
17. Riddle, B., and Jencks, W. P. (1971) J. Biol. Chem. 246, 3250-3258
18. Jencks, W. P., Gresser, M., Valenzuela, M. S., and Huneeus, F. C. (1972) J. Biol. Chem. 247, 3756-3760
19. Watanabe, M., Sofuni, T., and Nohmi, T. (1992) J. Biol. Chem. 267, 8429-8436
20. Sinclair, J., Sandy, J., Delgoda, R., Sim, E., and Noble, M. (2000) Nat. Struct. Biol. 7, 560-564
21. Graf, L., Hegyi, G., Liko, I., Hepp, J., Medzihradszky, K., Craik, C. S., and Rutter, W. J. (1988) Int. J. Pept. Protein Res. 32, 512-518
22. Turk, D., Guncar, G., Podobnik, M., and Turk, B. (1998) Biol. Chem. 379, 137-147
23. Sandy, J., Mushtaq, A., Kawanamura, A., Sim, E., and Noble, M. (2002) J. Mol. Biol., in press
24. Zinder, N. D., Model, P., and Boeke, J. D. (1986) U. S. Patent 416922
25. Mierendorf, R. C., Morris, B. B., Hammer, B., and Novy, R. E. (1998) Methods Mol. Med. 13, 257-292
26. Pan, S.-h., and Malcolm, B. A. (2000) BioTechniques 29, 1234-1236; 1238
27. Sinclair, J., Delgoda, R., Noble, M., Jarmin, S., Goh, N., and Sim, E. (1998) Protein Expr. Purif. 12, 371-380
28. Thorne, C. J. R. (1978) Tech. Life Sci. Biochem. Sect. B 104, 1-18
29. Sim, R. B., and Sim, E. (1981) Biochem. J. 193, 129-141
30. Pagano, M. (1999) Anal. Chim. Acta 383, 119-125
31. Lawson, C. L., and Hanson, R. T. (1974) Solving Least Squares Problems , Prentice-Hall, Englewood
32. Björk, Å. (1967) BIT (Tidskrift for Informations Behandling) Numerical Mathematics 7, 1-21
33. Watanabe, T., and Natori, M. (1989) in in Numerical Calculation Software, Trans. Japanese (Oguni, T., ed) , Maruzen, Tokyo
34. Ward, A., Summers, M., and Sim, E. (1995) Biochem. Pharmacol. 49, 1759-1767
35. Hutchings, A., Monie, R. D., Spragg, B., and Routledge, P. A. (1983) J. Chromatogr. 277, 385-390
36. www.tripos.com. (2000) TRIPOS (SYBYL), Version 6.5
37. Morris, D., Goodsell, D., Huey, R., and Olson, A. (1996) J. Comput.-aided Mol. Des. 10, 293-304
38. Morris, G., Goodsell, D., Halliday, R., Huey, R., Hart, W., Belew, R., and Olson, A. (1998) J. Comput. Chem. 19, 1639-1662
39. Guex, N., and Peitsch, M. C. (1997) Electrophoresis 18, 2714-2723
40. Hutchins, B., Bothones, N., and Peterson, W. (1941) J. Biol. Chem. 141, 521-528
41. Walker, J., and Miroux, B. (1998) United Kingdom PCT Patent W09802559
42. Davis, N. G., Boeke, J. D., and Model, P. (1985) J. Mol. Biol. 181, 111-121
43. Vasquez, J. R., Evnin, L. B., Higaki, J. N., and Craik, C. S. (1989) J. Cell. Biochem. 39, 265-276
44. Dalbey, R. E., and Wickner, W. (1985) J. Biol. Chem. 260, 15925-15931
45. Sinclair, J., and Sim, E. (1997) Biochem. Pharmacol. 53, 11-16
46. Takamura, Y., and Nomura, G. (1988) J. Gen. Microbiol. 134, 2249-2253
47. Pruess, B. M., and Wolfe, A. J. (1994) Mol. Microbiol. 12, 973-984
48. Ueyama, M., Tori, K., Ikehara, M., and Kaneko, M. (1974) Nucleic Acids Res. 1, 823-834
49. Mieyal, J. J., Webster, L. T., Jr., and Siddiqui, U. A. (1974) J. Biol. Chem. 249, 2633-2640
50. Laskowski, R. A., Hutchison, E. G., Michie, A. D., Wallace, A. C., Jones, M. L., and Thornten, J. M. (1997) Trends Biochem. Sci. 22, 488-490


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
Y. Zang, M. A. Doll, S. Zhao, J. C. States, and D. W. Hein
Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2
Carcinogenesis, August 1, 2007; 28(8): 1665 - 1671.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. M. Walraven, J. O. Trent, and D. W. Hein
Computational and Experimental Analyses of Mammalian Arylamine N-Acetyltransferase Structure and Function
Drug Metab. Dispos., June 1, 2007; 35(6): 1001 - 1007.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
J. M. Walraven, M. A. Doll, and D. W. Hein
Identification and Characterization of Functional Rat Arylamine N-Acetyltransferase 3: Comparisons with Rat Arylamine N-Acetyltransferases 1 and 2
J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 369 - 375.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. J. Butcher, A. Arulpragasam, and R. F. Minchin
Proteasomal Degradation of N-Acetyltransferase 1 Is Prevented by Acetylation of the Active Site Cysteine: A MECHANISM FOR THE SLOW ACETYLATOR PHENOTYPE AND SUBSTRATE-DEPENDENT DOWN-REGULATION
J. Biol. Chem., May 21, 2004; 279(21): 22131 - 22137.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
S. Bhakta, G. S. Besra, A. M. Upton, T. Parish, C. Sholto-Douglas-Vernon, K. J.C. Gibson, S. Knutton, S. Gordon, R. P. daSilva, M. C. Anderton, et al.
Arylamine N-Acetyltransferase Is Required for Synthesis of Mycolic Acids and Complex Lipids in Mycobacterium bovis BCG and Represents a Novel Drug Target
J. Exp. Med., May 3, 2004; 199(9): 1191 - 1199.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. Dairou, N. Atmane, F. Rodrigues-Lima, and J.-M. Dupret
Peroxynitrite Irreversibly Inactivates the Human Xenobioticmetabolizing Enzyme Arylamine N-Acetyltransferase 1 (NAT1) in Human Breast Cancer Cells: A CELLULAR AND MECHANISTIC STUDY
J. Biol. Chem., February 27, 2004; 279(9): 7708 - 7714.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. E. Summerscales and P. D. Josephy
Human Acetyl CoA:Arylamine N-Acetyltransferase Variants Generated by Random Mutagenesis
Mol. Pharmacol., January 1, 2004; 65(1): 220 - 226.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
N. Atmane, J. Dairou, A. Paul, J.-M. Dupret, and F. Rodrigues-Lima
Redox Regulation of the Human Xenobiotic Metabolizing Enzyme Arylamine N-Acetyltransferase 1 (NAT1): REVERSIBLE INACTIVATION BY HYDROGEN PEROXIDE
J. Biol. Chem., September 12, 2003; 278(37): 35086 - 35092.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/14/12175    most recent
M104365200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mushtaq, A.
Right arrow Articles by Sim, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mushtaq, A.
Right arrow Articles by Sim, E.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement